Published in J Neuroinflammation on June 21, 2014
Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. Alzheimers Res Ther (2015) 0.75
Sialic Acid within the Glycosylphosphatidylinositol Anchor Targets the Cellular Prion Protein to Synapses. J Biol Chem (2016) 0.75
Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease. Front Pharmacol (2015) 0.75
Oxidative stress and expression of insulin signaling proteins in the brain of diabetic rats: Role of Nigella sativa oil and antidiabetic drugs. PLoS One (2017) 0.75
CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (1990) 17.86
Lipid rafts as a membrane-organizing principle. Science (2010) 13.48
Signaling--2000 and beyond. Cell (2000) 11.78
Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med (2006) 6.15
Statins and the risk of dementia. Lancet (2000) 5.65
Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol (2006) 4.94
Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol (2007) 4.13
Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature (1996) 3.92
The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol (1988) 3.69
Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 3.60
Lipid rafts: heterogeneity on the high seas. Biochem J (2004) 3.46
Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity (1996) 3.33
Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci (2002) 3.29
Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol (2002) 3.24
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation (2008) 3.19
Plasma membranes are poised for activation of raft phase coalescence at physiological temperature. Proc Natl Acad Sci U S A (2008) 2.97
beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci (2001) 2.81
Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A (2010) 2.70
CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci (2009) 2.69
Rafts: scale-dependent, active lipid organization at the cell surface. Traffic (2004) 2.64
NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging (2006) 2.55
Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology (2009) 2.32
Fc epsilon RI-mediated recruitment of p53/56lyn to detergent-resistant membrane domains accompanies cellular signaling. Proc Natl Acad Sci U S A (1995) 2.30
Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic (2004) 2.28
Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A (1995) 2.24
Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem (2007) 2.12
Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol (1999) 2.10
Neuroinflammation in Alzheimer's disease and prion disease. Glia (2002) 1.86
Divergent response to LPS and bacteria in CD14-deficient murine macrophages. J Immunol (2000) 1.84
Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2008) 1.67
Monokine production by microglial cell clones. Eur J Immunol (1989) 1.64
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation (2008) 1.45
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci (2006) 1.39
Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol (2007) 1.34
Innate immune receptor expression in normal brain aging. Neuroscience (2007) 1.34
Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation (2007) 1.30
Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-alpha production by cells in whole blood. J Immunol (1994) 1.29
TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease. J Neuroinflammation (2011) 1.26
The inner side of T cell lipid rafts. Immunol Lett (2004) 1.26
Insulin-stimulated diacylglycerol production results from the hydrolysis of a novel phosphatidylinositol glycan. J Biol Chem (1987) 1.26
The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. J Neurochem (2000) 1.23
Clustering of raft-associated proteins in the external membrane leaflet modulates internal leaflet H-ras diffusion and signaling. Mol Cell Biol (2006) 1.18
Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther (2007) 1.13
Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging (2001) 1.12
Regulation of CD14 expression on human adult central nervous system-derived microglia. J Neurosci Res (1996) 1.11
Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol (1995) 1.10
Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J Neurosci (2010) 1.09
Microglial activation in Alzheimer's disease. Curr Alzheimer Res (2009) 1.06
Ethanol induces TLR4/TLR2 association, triggering an inflammatory response in microglial cells. J Neurochem (2013) 1.04
Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. Neuroreport (1999) 1.04
Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis. J Neuroinflammation (2014) 1.03
Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res Brain Res Rev (1997) 0.98
Role of the brain in interleukin-6 modulation. Neuroimmunomodulation (1998) 0.96
Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res (2009) 0.94
Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. Br J Haematol (2000) 0.93
The sulphonylurea drug, glimepiride, stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane proteins from 3T3 adipocytes. Biochem J (1993) 0.93
Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-alpha. Brain Res (1997) 0.90
Interleukin-6 inhibits neurotransmitter release and the spread of excitation in the rat cerebral cortex. Eur J Neurosci (2000) 0.89
Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport. J Cell Biol (1994) 0.89
Microglial cells kill prion-damaged neurons in vitro by a CD14-dependent process. J Neuroimmunol (2005) 0.85
Decay-accelerating factor (DAF/CD55) is a functional active element of the LPS receptor complex. J Endotoxin Res (2001) 0.85
Insulin-mimetic signaling by the sulfonylurea glimepiride and phosphoinositolglycans involves distinct mechanisms for redistribution of lipid raft components. Biochemistry (2001) 0.85
Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz) (2003) 0.82
Amino-terminally truncated prion protein PrP90-231 induces microglial activation in vitro. Ann N Y Acad Sci (2007) 0.82
Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines. PLoS One (2009) 0.82
ESeroS-GS modulates lipopolysaccharide-induced macrophage activation by impairing the assembly of TLR-4 complexes in lipid rafts. Biochim Biophys Acta (2011) 0.79
Cysteine-less glycosylphosphatidylinositol-specific phospholipase C is inhibited competitively by a thiol reagent: evidence for glyco-mimicry by p-chloromercuriphenylsulphonate. Biochem J (2002) 0.77
Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res Clin Pract (1995) 0.76
Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol (2004) 1.52
Amyloid-β-induced synapse damage is mediated via cross-linkage of cellular prion proteins. J Biol Chem (2011) 1.29
Gene expression profiling of the preclinical scrapie-infected hippocampus. Biochem Biophys Res Commun (2005) 1.21
Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem (2004) 1.19
Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication. J Biol Chem (2004) 1.08
Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation. BMC Biol (2008) 1.06
Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport (2007) 1.04
Inducible cytokine gene expression in the brain in the ME7/CV mouse model of scrapie is highly restricted, is at a strikingly low level relative to the degree of gliosis and occurs only late in disease. J Gen Virol (2003) 0.97
Neurodegeneration induced by clustering of sialylated glycosylphosphatidylinositols of prion proteins. J Biol Chem (2012) 0.95
α-synuclein induced synapse damage is enhanced by amyloid-β1-42. Mol Neurodegener (2010) 0.93
Microglia kill amyloid-beta1-42 damaged neurons by a CD14-dependent process. Neuroreport (2004) 0.93
The role of platelet activating factor in prion and amyloid-beta neurotoxicity. Neuroreport (2004) 0.93
Phospholipase A2 inhibitors protect against prion and Abeta mediated synapse degeneration. Mol Neurodegener (2010) 0.92
Interferon-gamma increases neuronal death in response to amyloid-beta1-42. J Neuroinflammation (2006) 0.90
Genomics of elite sporting performance: what little we know and necessary advances. Adv Genet (2013) 0.90
Manipulation of PrPres production in scrapie-infected neuroblastoma cells. J Neurosci Methods (2004) 0.89
Monoacylated cellular prion protein modifies cell membranes, inhibits cell signaling, and reduces prion formation. J Biol Chem (2011) 0.89
The glycosylphosphatidylinositol anchor is a major determinant of prion binding and replication. Biochem J (2010) 0.89
Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by Abeta(1-42). Neuropharmacology (2007) 0.89
The molecular assembly of amyloid aβ controls its neurotoxicity and binding to cellular proteins. PLoS One (2011) 0.88
Glycosylphosphatidylinositol anchor analogues sequester cholesterol and reduce prion formation. J Biol Chem (2010) 0.87
Neurones treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid-beta1-42. Neuroreport (2003) 0.86
The N-methylated peptide SEN304 powerfully inhibits Aβ(1-42) toxicity by perturbing oligomer formation. Biochemistry (2012) 0.86
Prostaglandin D2 mediates neuronal damage by amyloid-beta or prions which activates microglial cells. Neuropharmacology (2005) 0.85
Microglial cells kill prion-damaged neurons in vitro by a CD14-dependent process. J Neuroimmunol (2005) 0.85
Temporal and spatial relationship between the death of PrP-damaged neurones and microglial activation. Neuroreport (2002) 0.85
Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to HuPrP82-146 and Abeta 1-42. Neuropharmacology (2008) 0.83
Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta1-42. J Neuroinflammation (2004) 0.83
Platelet-activating factor antagonists protect amyloid-beta damaged neurons from microglia-mediated death. Neuropharmacology (2006) 0.82
Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines. PLoS One (2009) 0.82
Ginkgolides protect against amyloid-beta1-42-mediated synapse damage in vitro. Mol Neurodegener (2008) 0.81
Ethanol protects cultured neurons against amyloid-β and α-synuclein-induced synapse damage. Neuropharmacology (2011) 0.81
Polyunsaturated fatty acids protect against prion-mediated synapse damage in vitro. Neurotox Res (2009) 0.81
Cyclo-oxygenase inhibitors protect against prion-induced neurotoxicity in vitro. Neuroreport (2002) 0.80
Role of glycosylphosphatidylinositols in the activation of phospholipase A2 and the neurotoxicity of prions. J Gen Virol (2004) 0.80
A role for B lymphocytes in anti-infective prion therapies? Expert Rev Anti Infect Ther (2007) 0.79
Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biol (2008) 0.79
An adapted ImmunoMagnetic cell separation method for use in quantification of Escherichia coli O157:H7 from bovine faeces. J Microbiol Methods (2003) 0.79
Clustering of sialylated glycosylphosphatidylinositol anchors mediates PrP-induced activation of cytoplasmic phospholipase A 2 and synapse damage. Prion (2012) 0.79
Inhibition of phospholipase A2 increased the removal of the prion derived peptide PrP82-146 from cultured neurons. Neuropharmacology (2010) 0.79
Amyloid-β(1-40) inhibits amyloid-β(1-42) induced activation of cytoplasmic phospholipase A2 and synapse degeneration. J Alzheimers Dis (2010) 0.78
Detoxified lipopolysaccharide reduces microglial cell killing of prion-infected neurons. Neuroreport (2004) 0.77
Cholesterol esterification reduces the neurotoxicity of prions. Neuropharmacology (2008) 0.77
Squalestatin alters the intracellular trafficking of a neurotoxic prion peptide. BMC Neurosci (2007) 0.76
Cholesterol synthesis inhibitors protect against platelet-activating factor-induced neuronal damage. J Neuroinflammation (2007) 0.76
A glycosylphosphatidylinositol analogue reduced prion-derived peptide mediated activation of cytoplasmic phospholipase A2, synapse degeneration and neuronal death. Neuropharmacology (2010) 0.76
The cellular prion protein with a monoacylated glycosylphosphatidylinositol anchor modifies cell membranes, inhibits cell signaling and reduces prion formation. Prion (2011) 0.76
An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds. Anal Biochem (2004) 0.76
Inhibition of cytosolic Phospholipase A2 prevents prion peptide-induced neuronal damage and co-localisation with Beta III Tubulin. BMC Neurosci (2012) 0.76
Ensuring a sustainable profession. Vet Rec (2013) 0.75
Re. Bhat et al., 2012 [JPU (2012) 8: 348-353]. J Pediatr Urol (2012) 0.75
Sinonasal glomangiopericytoma: Is anything new? Ear Nose Throat J (2016) 0.75
Early experience with the Mills sleeve prosthesis for reconstruction of the incus long process. J Laryngol Otol (2004) 0.75